Navigation Links
Maxygen Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/12/2008

nts. These and other risk factors are more fully discussed in our Form 10-K for the year ended December 31, 2006, including under the caption "Risk Factors", and in our other periodic SEC reports, all of which are available from Maxygen at http://www.maxygen.com. Maxygen disclaims any obligation to update or revise any forward-looking statement contained in this release as a result of new information or future events or developments.

Selected Consolidated Financial Information

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

(unaudited) (unaudited) (Note 1)

Revenues:

Collaborative research and

development revenue $1,756 $5,326 $10,232 $20,544

Revenue from related party 7,696 -- 8,286 --

Grant revenue 1,529 1,184 4,639 4,477

Total revenues 10,981 6,510 23,157 25,021

Expenses:

Research and development 15,338 13,636 59,851 49,130

General and administrative 3,141 4,629 14,951 17,559

Restructuring charges 5,212 -- 5,212 --

Total operating expenses 23,691 18,265 80,014 66,689

Loss from operations (12,710)(11,755) (56,857) (41,668)

Interest income and other

(expense), net 1,436 2,433 7,542 8,524

Equity in net losses of minority

interests -- --
'/>"/>

SOURCE Maxygen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Maxygen to Present at the Roth 20th Annual OC Growth Stock Conference
2. Maxygen to Present at the Stanford Group Company 13th Annual Healthcare Conference
3. Maxygen to Present at the JPMorgan 26th Annual Healthcare Conference
4. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
5. Maxygen Reports Third Quarter 2007 Financial Results
6. Maxygen Announces Upcoming Webcasts at Investor Conferences
7. Maxygen Third Quarter 2007 Financial Results Conference Call Notice
8. Maxygen Announces Hold on MAXY-alpha Development Program
9. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
10. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
11. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... One of the major limitations in ... vascular supply. Nutrient and gas transport throughout synthetic ... for successful regeneration and integration into the patient’s ... vascularization and promote angiogenesis in a variety of ... and architecture, and enhancing scaffolds with stem cells. ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 ... to raise $200,000 to fund a corporate lab ... , This development is a critical component ... of care to the implementation of personalized medicine ... of practicing medicine. , Indiegogo contributions will support ...
(Date:8/19/2014)... 2014 Research and Markets ... "Spectroscopy Equipment and Accessories - Global ... offering. This report analyzes ... Accessories in US$ Thousands by the following ... Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, ...
(Date:8/19/2014)... - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ... Oral Amphotericin B (Oral Amp B) drug candidate ... ImmuneCarta®, the immune monitoring business unit of Caprion, ... Amp B in reactivating latent HIV viral reservoirs ... with antiretroviral therapy. Memory cells, ...
Breaking Biology Technology:Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3
... approves Intercell,s first marketed product, a new vaccine against ... product launch in the U.S. planned for Q2 2009VIENNA, ... that the U.S. Food and Drug Administration (FDA) approved ... Encephalitis (JE). The initial target for use of Intercell,s ...
... Mylan Inc. (Nasdaq: MYL ) today ... which it holds a 71.2% controlling interest, has received ... Drug Administration (FDA) under the President,s Emergency Plan for ... (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 ...
... WALTHAM, Mass., March 30 Inverness Medical Innovations, Inc. (NYSE: ... to take charge of their health at home through the ... dividend of $3.00 per share on its Series B Convertible ... in shares of Series B stock in an amount per ...
Cached Biology Technology:Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 2Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 3Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 4Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R) 2
(Date:8/20/2014)... at Huntsman Cancer Institute (HCI) at the University of ... gene that encodes BCR-ABL, the unregulated enzyme driving the ... American Cancer Society, nearly 6,000 new cases of CML ... use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL and ... cure CML but control it in a way that ...
(Date:8/20/2014)... fires are visible in in this image of the ... of these were most likely intentionally set in order ... a forest or stand of trees where the land ... deforestation include conversion of forestland to farms, ranches, or ... dark green of the Amazon Rainforest in the middle ...
(Date:8/20/2014)... Research UK scientists have discovered that acral melanomas the ... Marley,s death are genetically distinct from other more common ... external) published in the journal Pigment Cell & Melanoma ... of the hands, soles of the feet, nail-beds and other ... of melanoma, it,s not caused by UV damage from the ...
Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Scientists learn more about rare skin cancer that killed Bob Marley 2
... Increasing block-rate water budgets are an innovative type ... block sizes are based on household characteristics, environmental conditions, ... to what constitutes "efficient" water use given those characteristics ... set relatively low for the most essential uses of ...
... the most serious are poverty, the growing demand for ... to satisfy the growing demand for wood, forestry in ... the Russian Federation are the world,s largest reserve of ... will result in increasing availability of wood for material ...
... of data related to climate change are being compiled ... these many and various sources results in different climate ... data sets to arrive at a consensus regarding future ... December in the SIAM Journal on Uncertainty Quantification ...
Cached Biology News:An innovative approach to promote water use efficiency 2An innovative approach to promote water use efficiency 3Sustainable use of energy wood resources shows potential in North-West Russia 2Sustainable use of energy wood resources shows potential in North-West Russia 3Statistics research could build consensus around climate predictions 2Statistics research could build consensus around climate predictions 3Statistics research could build consensus around climate predictions 4
... Kit is intended for quantitative detection of ... which can result from the gradual, nonenzymatic ... acid residues during storage or handling. Because ... monitoring of charge differences for detection, charge ...
...
... siRNA and miRNA Isolation Traditional mRNA ... mRNA and can result in the loss ... mirVana miRNA Isolation Kit purifies all RNA ... double-stranded. Through an enrichment procedure included in ...
ABI Plant AFLP Kits • EcoRI-ACA AFLP Amplification Primers...
Biology Products: